Pharmaceutical Technology

NOVEMBER 9, 2022

Despite their potential multi-million-dollar sticker price, if haemophilia treatments by BioMarin and CSL Behring prove durable, they could help patients save money compared to current treatments, experts note. A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96

Safety 111

Safety Pharmaceutical Patients Medicine 111

Pharmaceutical Technology

JUNE 21, 2023

CSL announced the first patient with haemophilia B has been treated with its recently approved gene therapy Hemgenix (etranacogene dezaparvovec). Hemgenix is the first and only gene therapy approved for haemophilia B. Haemophilia B is a rare condition. per dose, it is the most expensive single-use gene therapy in the US.

Patients 98

Patients Food and Drug Administration Engineering Sales 98

pharmaphorum

AUGUST 26, 2022

BioMarin Pharma has its landmark first approval for Roctavian – the first for a haemophilia gene therapy – and will now have to see if that can convert that into a viable business in Europe. million spread over five years.

FDA 109

FDA Marketing Competition Patients 109

pharmaphorum

NOVEMBER 16, 2022

However, with a price tag of €1.58 However, a recently released report from the organisation could blow the price tag of Zolgensma out of the water. Both of the treatments are gene therapies for haemophilia, and both are one-time therapies. How to navigate the new climate. At more than $2.1

Medicine 124

Medicine Marketing Healthcare Healthcare 124